Profile
Jessica Stitt is former Chief Financial Officer for Gyroscope Therapeutics Holdings Plc, former Vice President-Finance & Investor Relations at Theravance Biopharma, Inc. and former Vice President-Finance & Operations at MyoKardia, Inc.
Ms. Stitt received an undergraduate degree from St. Anselm College and an MBA from Simmons School of Management.
Former positions of Jessica Stitt
Companies | Position | End |
---|---|---|
GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director of Finance/CFO | 2022-03-31 |
MYOKARDIA, INC. | Corporate Officer/Principal | 2020-12-31 |
THERAVANCE BIOPHARMA, INC. | Public Communications Contact | - |
Training of Jessica Stitt
St. Anselm College | Undergraduate Degree |
Simmons School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
THERAVANCE BIOPHARMA, INC. | Health Technology |
Private companies | 2 |
---|---|
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Gyroscope Therapeutics Holdings Plc
Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |